Marksans Pharma Limited (MARKSANS) AI Stock Analysis

• Market Cap: ₹84.65B
• Dividend Yield: 0.43%
• Average Volume (3M): 544.70K
• Price to Earnings (P/E): 24.2
• Beta (1Y): 1.58
• Revenue Growth: 16.94%
• EPS Growth: 4.90%
• Country: IN
• Employees: 1,141
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - General
• EPS (TTM): 1.29
• Shares Outstanding: 453,163,760
• 10 Day Avg. Volume: 96,187
• 30 Day Avg. Volume: 544,697
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹271.00
• Price Target Upside: 45.07% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 69 Neutral
• Price Target: ₹271.00 ▲(45.07% Upside)

Marksans Pharma Limited's strong financial performance, characterized by robust growth and profitability, significantly contributes to its stock score. However, technical indicators suggest weak momentum, which, combined with a high P/E ratio, indicates the stock may face short-term challenges. The overall valuation is moderate, reflecting mixed signals from both fundamental and technical perspectives.

Marksans Pharma Limited Business Overview & Revenue Model

Company Description

Marksans Pharma Limited is a global pharmaceutical company engaged in the research, development, manufacturing, and marketing of a wide range of generic pharmaceutical products. Headquartered in India, Marksans operates within the pharmaceutical and healthcare sectors, focusing on producing tablets, capsules, ointments, and other dosage forms. The company specializes in a diverse array of therapeutic segments, including pain management, cardiovascular, anti-diabetic, gastroenterology, and antibiotic medications.

How the Company Makes Money

Marksans Pharma Limited generates revenue primarily through the sale of its generic pharmaceutical products across various international markets. The company's key revenue streams include manufacturing and distributing a broad portfolio of generic drugs to wholesalers, distributors, hospitals, and pharmacies. Marksans capitalizes on its robust manufacturing capabilities and cost-efficient operations to offer competitively priced medications. Additionally, the company benefits from strategic partnerships and alliances with other pharmaceutical entities, which enhance its market reach and distribution network. Marksans also invests in research and development to expand its product portfolio, catering to the growing demand for affordable healthcare solutions globally.

Marksans Pharma Limited Financial Statement Overview

Summary

Marksans Pharma Limited demonstrates robust financial health with strong revenue growth, impressive profit margins, and a solid balance sheet with low leverage. While cash flow from operations has decreased, efficient capital expenditure management has led to increased free cash flow. Overall, the financial position is strong, albeit with a need to monitor cash flow volatility.

Income Statement

Marksans Pharma Limited shows a strong revenue growth trajectory with a 20.45% increase from the previous year. The Gross Profit Margin remains solid at 56.38% for the latest period, indicating effective cost management. The Net Profit Margin also improved to 14.51%, reflecting enhanced profitability. Margins such as EBIT at 43.04% and EBITDA at 20.15% showcase operational efficiency. Overall, the income statement indicates a strong financial performance with robust growth and profitability.

Balance Sheet

The balance sheet reflects a healthy financial position with a strong Equity Ratio of 76.14%, suggesting a low reliance on debt for financing. The Debt-to-Equity Ratio remains low at 0.13, indicating minimal financial leverage. Return on Equity (ROE) stands at 15.42%, showing good returns to shareholders. The company's stability is further reinforced by a substantial stockholders' equity base, though the moderate increase in total liabilities warrants attention.

Cash Flow

Cash flow statements reveal a noticeable decrease in Operating Cash Flow by 10.28% compared to the previous year. However, Free Cash Flow saw a significant increase by 56.44%, indicating improved cash management despite lower operating cash flow. The Operating Cash Flow to Net Income Ratio of 0.54 suggests some volatility in cash generation relative to profits. Overall, cash flow performance is solid but highlights areas for potential improvement in cash generation from operations.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	26.23B	21.77B	18.52B	14.80B	13.68B
Gross Profit	14.79B	10.83B	9.31B	7.32B	7.50B
EBITDA	5.29B	5.09B	3.99B	3.01B	3.46B
Net Income	3.81B	3.14B	2.66B	1.85B	2.39B
Balance Sheet
Total Assets	32.40B	26.81B	21.90B	16.40B	12.28B
Cash, Cash Equivalents and Short-Term Investments	7.05B	7.00B	7.19B	3.47B	2.09B
Total Debt	3.22B	2.44B	1.23B	1.11B	341.02M
Total Liabilities	7.50B	5.95B	4.25B	4.17B	3.23B
Stockholders Equity	24.67B	20.65B	17.45B	12.02B	8.86B
Cash Flow
Free Cash Flow	337.45M	215.69M	1.84B	529.27M	1.32B
Operating Cash Flow	2.07B	2.30B	2.37B	992.57M	1.79B
Investing Cash Flow	-490.09M	-1.41B	-2.59B	-416.86M	-448.96M
Financing Cash Flow	-651.46M	-687.27M	1.98B	795.11M	-152.86M

Marksans Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 186.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MARKSANS, the sentiment is Negative. The current price of 186.8 is below the 20-day moving average (MA) of 232.91, below the 50-day MA of 245.27, and below the 200-day MA of 253.96, indicating a bearish trend. The MACD of -9.77 indicates Positive momentum. The RSI at 26.25 is Positive, neither overbought nor oversold. The STOCH value of 12.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MARKSANS.

Marksans Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	71 Outperform	₹614.49B	18.12		0.38%	7.76%	-2.83%
DRREDDY	70 Outperform	₹1.02T	17.92		0.65%	15.76%	2.01%
MARKSANS	69 Neutral	₹84.65B	24.18		0.43%	16.94%	4.90%
IPCALAB	66 Neutral	₹349.17B	44.84		0.29%	11.49%	35.00%
GLENMARK	62 Neutral	₹580.50B	55.43		0.12%	9.39%	―
LAURUSLABS	54 Neutral	₹448.51B	88.08		0.14%	17.31%	242.99%
Sector *	51 Neutral	$7.42B	-0.36	-44.95%	2.27%	22.89%	-2.16%

Marksans Pharma Limited Corporate Events

Marksans Pharma Announces AGM Notice Addendum

Marksans Pharma Limited has announced an addendum to the notice of its 33rd Annual General Meeting, as published in the Business Standard and Lakshadeep newspapers. This announcement is part of the company’s compliance with regulatory requirements, reflecting its commitment to transparency and effective communication with stakeholders.

Marksans Pharma Appoints New Secretarial Auditor for Five-Year Term

Marksans Pharma Limited has announced the appointment of M/s Jinesh Dedhia & Associates as the Secretarial Auditor for a five-year term starting from April 1, 2025, to March 31, 2030. This strategic move is part of the company’s compliance with regulatory requirements and aims to enhance its governance practices, potentially strengthening its market position and stakeholder confidence.